Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The figures above are research-context reference points only
Recent studies are investigating its use in the treatment of obesity, non-alcoholic steatohepatitis (NASH), and even Alzheimers disease, suggesting that the impact of this drug could reach well beyond its current applications
For patients, it means weighing potential benefits against theoretical unknowns
A few highlights: Accelerated eGFR decline during the year preceding a heart failure event Slower decline afterward but still exacerbated A parallel between eGFR slope and NYHA class, suggesting the kidney may be signaling congestion early These findings call for a shift in practice: instead of relying on static eGFR thresholds, tracking its trajectory over time could help us identify at-risk patients sooner and intervene before hospitalization
US$ 23.93
US$ 26.84
US$ 21.45
US$ 25.02
